Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received a consensus rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $43.1429.

Several research firms have recently weighed in on ZBIO. Wall Street Zen lowered shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research report on Tuesday, December 16th. Morgan Stanley downgraded shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $37.00 to $19.00 in a research report on Monday, January 5th. Wedbush reissued an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a research note on Monday, December 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th.

Zenas BioPharma Stock Up 8.7%

Shares of ZBIO opened at $19.72 on Wednesday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -2.79 and a beta of -1.50. Zenas BioPharma has a 52 week low of $6.11 and a 52 week high of $44.60. The stock’s 50-day moving average price is $30.01 and its 200-day moving average price is $25.30. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Activity

In related news, CEO Leon O. Moulder, Jr. bought 57,000 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was acquired at an average price of $17.96 per share, with a total value of $1,023,720.00. Following the completion of the purchase, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. This trade represents a 15.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have bought a total of 157,000 shares of company stock valued at $2,662,720 in the last quarter. 16.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zenas BioPharma

Several large investors have recently bought and sold shares of ZBIO. Federated Hermes Inc. lifted its position in shares of Zenas BioPharma by 60.8% in the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after acquiring an additional 703,838 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after purchasing an additional 290,307 shares in the last quarter. Geode Capital Management LLC boosted its stake in Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares during the last quarter. Invesco Ltd. acquired a new stake in Zenas BioPharma during the 3rd quarter worth $3,237,000. Finally, Millennium Management LLC purchased a new stake in shares of Zenas BioPharma during the third quarter worth $1,595,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.